Infections following chimeric antigen receptor T cell therapy: 2018–2022
Transplant Infectious Disease · 2024
DOI: 10.1111/tid.14376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Vishakh C Keri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious diseases, Wayne State University, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Chimeric antigen receptor (CAR) T‐cell therapy is an emerging therapeutic modality for relapsed and refractory hematological malignancies. Infectious complications following CAR T‐cell therapy are not well defined.
Methods
This is a retrospective analysis of data on patients who received CAR T‐cell therapy between April 2018 and December 2022 at the Karmanos Cancer Center, Detroit. Patients’ data were collected up to their last known clinic or inpatient follow‐up visit. An infectious episode was defined as any microbiologically proven or clinically documented infection.
Results
Seventy‐six patients received therapy with FDA‐approved CAR T‐cell products. Thirty‐three patients (43.4%) had at least one infectious episode. There were 61 infectious episodes during a median follow‐up of 184 (96–340) days. Median duration for the onset of infection was 59 (22–209) days. Bacterial and viral infections occurred in 42.6% and 41% of the infectious episodes, respectively. COVID‐19 was the most common infectious complication (14.8%). Time‐to‐event analysis showed that most infections occurred within the first 100 days. Empirical antibiotic use during Cytokine Release Syndrome/Immune effector Cell‐Associated Neurotoxicity Syndrome (CRS/ICANS) in the absence of documented bacterial infection was reported in 85.7% of patients. Clostridioides difficile accounted for 11.5% of all infectious episodes. Five of six patients with C. difficile infection had CRS/ICANS and received antibiotics.
Conclusion
COVID‐19 and C. difficile infection were the most common infections following CAR T‐cell therapy. Most infections occurred within the first 100 days. Empiric antibiotic use and C. difficile infection were common in patients with CRS/ICANS, in the absence of documented bacterial infection, thus providing an excellent opportunity for antimicrobial stewardship in this population. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious diseases, Wayne State University, Detroit, Michigan, USA.
- Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA.
- Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
- Division of Infectious diseases, Karmanos Cancer Center, Wayne State University, Detroit, Michigan, USA.
ORCID-Profile: Vishakh C Keri
Zitieren
APA
Keri, V. C., Monday, L. M., Ramakrishna, J. M., Vyas, R., Deol, A., Al-Saadi, M., & Chandrasekar, P. H. (2024). Infections following chimeric antigen receptor T cell therapy: 2018–2022. Transplant Infectious Disease. https://doi.org/10.1111/tid.14376
Vancouver
Keri VC, Monday LM, Ramakrishna JM, Vyas R, Deol A, Al-Saadi M, et al. Infections following chimeric antigen receptor T cell therapy: 2018–2022. Transplant Infectious Disease. 2024. doi:10.1111/tid.14376
BibTeX
@article{Keri2024,
author = {Keri, Vishakh C and Monday, Lea M and Ramakrishna, Jahanavi M and Vyas, Rahul and Deol, Abhinav and Al-Saadi, Mahmoud and Chandrasekar, Pranatharthi H},
title = {Infections following chimeric antigen receptor T cell therapy: 2018–2022},
journal = {Transplant Infectious Disease},
year = {2024},
doi = {10.1111/tid.14376}
}
EUVIMED